Treatment of T1185B melanoma cells with IFNγ or the proteasome inhibitor MG132 did not alter differently the presentation of PC and circRNA-BSJ derived peptides, suggesting they follow similar routes of antigen processing and presentation. The gene discussed is IFNG; the disease is melanoma.